Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients

[1]  J. Tie,et al.  RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. , 2016, Clinical colorectal cancer.

[2]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[3]  R. Schilsky,et al.  Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. , 2016, Journal of oncology practice.

[4]  J. Massagué,et al.  Metastatic colonization by circulating tumour cells , 2016, Nature.

[5]  Zhang Jun,et al.  Interpretation of NCCN Clinical Practice Guidelines in Oncology:Cervical Cancer (Version 1.2016) , 2016 .

[6]  The Lancet Oncology.  Liquid cancer biopsy: the future of cancer detection? , 2016, The Lancet. Oncology.

[7]  Meng Zhang,et al.  Incidence and mortality of colorectal cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[8]  Stefano Ferrero,et al.  Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma , 2015, PloS one.

[9]  P. Laurent-Puig,et al.  Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers , 2015, British Journal of Cancer.

[10]  Pei-Hong Wu,et al.  Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma , 2015, Chinese journal of cancer.

[11]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[12]  Claudia Maggi,et al.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.

[13]  Jin-Ling Tang,et al.  Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases , 2015, Scientific Reports.

[14]  G. Fontanini,et al.  Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer , 2015, International journal of cancer.

[15]  M. Saroufim,et al.  Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. , 2014, Experimental and molecular pathology.

[16]  H. Moch,et al.  Intratumor Heterogeneity in Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[17]  M. Vieth,et al.  Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation. , 2014, Human pathology.

[18]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Tabernero,et al.  Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Butler,et al.  Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial , 2014, The Lancet. Oncology.

[21]  Franck Molina,et al.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.

[22]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[23]  X. Pivot,et al.  Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. , 2013, The oncologist.

[24]  Victor Moreno,et al.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.

[25]  M. Kojima,et al.  KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer , 2012, British Journal of Cancer.

[26]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[27]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[28]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[29]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[30]  Lei-na Sun,et al.  Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice , 2011, Journal of experimental & clinical cancer research : CR.

[31]  I. Nagtegaal,et al.  KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.

[32]  Seung-Yong Jeong,et al.  Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer , 2011, Cancer Chemotherapy and Pharmacology.

[33]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[34]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[35]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[36]  F. Lévi,et al.  Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis , 2010, Cancer Chemotherapy and Pharmacology.

[37]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[38]  York Springer,et al.  Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .

[39]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[40]  H. Müller-Hermelink,et al.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy , 2010, Journal of oncology.

[41]  J. Feliu,et al.  KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis , 2009, PloS one.

[42]  D. Cunningham,et al.  Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  I. Floriani,et al.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.

[45]  P. Laurent-Puig,et al.  K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy , 2008, Clinical Cancer Research.

[46]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Bachellier,et al.  Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes , 2007, International journal of cancer.

[48]  R. Single,et al.  Surgical Resection of Primary Tumors in Patients Who Present With Stage IV Colorectal Cancer: An Analysis of Surveillance, Epidemiology, and End Results Data, 1988 to 2000 , 2005, Annals of Surgical Oncology.

[49]  A. Russo,et al.  Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.

[50]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[51]  A J Kermond,et al.  How can we reduce the incidence and mortality of colorectal cancer? , 1997, The Medical journal of Australia.